Trenbolone 100

Dragon Pharma Trenbolone 100 — Trenbolone Acetate 100mg/mL

Dragon Pharma Trenbolone 100 delivers 100 mg of Trenbolone Acetate per milliliter in a pharmaceutical-grade oil solution. This fast-acting 19-nortestosterone derivative is engineered for advanced athletes seeking exceptional muscular density and accelerated lipolysis.

The Acetate ester provides rapid onset within days alongside quick systemic clearance. This pharmacokinetic profile grants users precise control over dosing adjustments and rapid discontinuation if adverse effects emerge.

Overview

Trenbolone Acetate is a synthetic 19-nor steroid with potent progestogenic activity and zero aromatization potential. Its molecular structure prevents conversion to estradiol, eliminating estrogenic bloating and water retention entirely.

The compound exhibits one of the highest anabolic-to-androgenic ratios among injectable agents. It aggressively upregulates androgen receptor density while enhancing nutrient partitioning, directing caloric intake toward contractile tissue rather than adipose storage.

Users frequently report a chiseled, three-dimensional aesthetic characterized by pronounced striations and superficial vascularity. The Acetate ester's brief half-life necessitates frequent administration but allows for rapid plasma stabilization.

Dragon Pharma subjects every production batch to independent third-party analytical testing. Multiple assays have confirmed consistent potency at or above the labeled 100 mg/mL concentration, demonstrating exceptional manufacturing reliability.

Benefits

• Exceptional Muscular Density: Produces a hard, grainy appearance with visible fiber separation and striations unmatched by traditional anabolic compounds.
• Accelerated Lipolysis: Superior nutrient partitioning directs energy substrates toward lean tissue accretion while mobilizing stored body fat, even during caloric surplus.
• Explosive Strength Gains: Rapidly increases neuromuscular efficiency and load tolerance, supporting dramatic power improvements within the first 2–3 weeks.
• Zero Estrogenic Activity: The non-aromatizing structure prevents gynecomastia, subcutaneous edema, and estrogen-mediated hypertension.
• Rapid Onset and Clearance: The Acetate ester achieves peak activity within days and clears within 48–72 hours, providing maximum protocol flexibility.

Main Features

• 100 mg/mL Trenbolone Acetate in oil-based solution
• 19-nortestosterone derivative with high progestogenic affinity
• Complete absence of aromatization potential
• Short ester requiring every-other-day or daily administration
• 10 mL multi-dose vial for extended cycle use
• Independent laboratory verification of batch potency

Ingredients

Each milliliter contains 100 mg of Trenbolone Acetate as the active pharmaceutical ingredient.

The formulation utilizes pharmaceutical-grade carrier oils, benzyl alcohol as an antimicrobial preservative, and co-solvents to ensure stable suspension and optimal intramuscular absorption.

All raw materials undergo independent verification for identity, potency, and sterility prior to compounding.

How to Use

Administer via deep intramuscular injection into large muscle groups. Rotate between the gluteal region, vastus lateralis, and deltoids to prevent localized tissue fibrosis.

The Acetate ester requires every-other-day or daily injections to maintain stable plasma concentrations. Inconsistent dosing intervals produce hormonal fluctuations that amplify neuroendocrine side effects.

Always employ the Z-track technique and aspirate before depressing the plunger. This minimizes the risk of intravascular injection and the associated bronchospastic response.

Store unopened vials in a temperature-stable environment between 15–30°C (59–86°F), shielded from direct light. Do not freeze.

Dosage

First-time Trenbolone users should initiate at 50 mg every other day. This equates to approximately 175 mg weekly and allows for assessment of individual tolerance and progestogenic sensitivity.

Intermediate athletes typically administer 75 mg every other day, yielding roughly 262 mg weekly. This dose produces significant recomposition effects without excessive neuroendocrine burden.

Advanced users may escalate to 100 mg every other day, delivering approximately 350 mg weekly. This represents the upper threshold for most experienced athletes.

This compound is absolutely contraindicated for women. The extreme androgenic potency causes rapid, irreversible virilization even at micro-doses.

Limit continuous administration to 8–10 weeks maximum. Cumulative cardiovascular and neuroendocrine stress escalates substantially beyond this window.

Side Effects

A sudden bronchospastic cough may occur immediately following injection, particularly if the oil enters a small blood vessel. While alarming, this episode is typically self-limiting and resolves within minutes.

Cardiovascular strain is pronounced. Trenbolone frequently elevates blood pressure while suppressing HDL cholesterol and increasing hematocrit. Regular monitoring and cardiovascular support are mandatory.

The progestogenic nature can elevate prolactin levels, potentially causing gynecomastia distinct from estrogenic pathways, sexual dysfunction, and emotional lability. A dopamine agonist such as Cabergoline should remain on hand.

Neuroendocrine effects include insomnia, night sweats, and increased aggression or anxiety. These manifestations reflect the compound's potent central nervous system modulation and are often dose-dependent.

Androgenic sequelae such as acne, accelerated scalp hair thinning, and increased sebum production are common in genetically susceptible individuals.

Exogenous Trenbolone severely suppresses hypothalamic-pituitary-gonadal axis function. Endogenous testosterone production declines rapidly, necessitating immediate recovery protocols upon cessation.

Safety Information

This product is intended exclusively for research purposes and use by qualified male adults under appropriate supervision. It is not suitable for minors, women, or individuals with pre-existing cardiovascular, hepatic, renal, or psychiatric conditions.

A testosterone base is mandatory throughout the entire cycle. Trenbolone suppresses endogenous androgen production completely, and running it without exogenous testosterone leads to profound hypogonadal symptoms.

A dopamine agonist should be available for prolactin management. Do not administer prophylactically; reserve for symptomatic elevation confirmed by blood work.

Post-Cycle Therapy must commence within 3 days of the final injection due to the Acetate ester's rapid clearance. A comprehensive protocol using Clomiphene and Tamoxifen is essential for axis recovery.

Discontinue immediately and seek medical evaluation if severe chest pain, persistent cough with hemoptysis, profound mood disturbances, or uncontrolled hypertension develop.